Early and late effects of intravenous thrombolysis in acute myocardial infarction a natural history study by Jonathan Peter Fox

Cover of: Early and late effects of intravenous thrombolysis in acute myocardial infarction | Jonathan Peter Fox

Published by University of Birmingham in Birmingham .

Written in English

Read online

Edition Notes

Thesis (M.D.)- University of Birmingham, Department of Cardiovascular Medicine, 1991.

Book details

Statementby Jonathan Peter Fox.
ID Numbers
Open LibraryOL13929195M

Download Early and late effects of intravenous thrombolysis in acute myocardial infarction

Because late arrival still is a major limiting factor for early thrombolysis, a public educational program was started by which potential patients, their relatives, and the general medical community are informed about signs and symptoms of ischemic events and the chances and potential benefits of emergency management of by: The early history and development of thrombolysis in acute myocardial infarction A.

MAROO andE. TOPOL From the Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, OH, USA To cite this article: Maroo A, Topol EJ. The early history and development of thrombolysis in acute myocardial infarction.

J Thromb Haemost ;Cited by: It was a great pleasure for us to welcome so many experts from all over the world to our symposium in Aachen. Early and late effects of intravenous thrombolysis in acute myocardial infarction book We are also pleased - and you can attribute this to my own vanity - with the success and a.

Yusuf S, Collins R, Peto R, Furberg C, Stamper MJ, Gaddhaber ST, Henmekens CH () Intravenous and intracoronary fibrinolytic therapy in acute myocardial infarction: overview of results on mortality, re-infarction and side-effects from 33 randomized controlled by: 3.

Embolic stroke shortly after systemic thrombolysis has been described in acute myocardial ischemia and prosthetic valve thrombosis and more recently in a few cases of acute ischemic stroke. We describe a series of cases wherein early recurrent ischemic stroke (ERIS), confirmed clinically and radiologically, occurred shortly after IV rt-PA, and Cited by: The first clinical trial that critically examined the differences between IV SK and rt-PA was the Thrombolysis in Myocardial Infarction (TIMI) Trial, phase l.

14 This trial was designed to compare the relative thrombolytic activity and side effects of IV t-PA and IV SK in patients with acute MI and angiographically documented, infarct-related total occlusion of the coronary by: Early thrombolysis for the treatment of acute myocardial infarction: a rapid and systematic review.

Health Technol Assess [in press] ABOUT HOME UNIT The Liverpool Reviews and Implementation Group (LRIG) was established within the Department of Pharmacolocy and Therapeutics in April It is a multi-disciplinary research group whose.

Background: Many trials have been done to compare primary percutaneous transluminal coronary angioplasty (PTCA) with thrombolytic therapy for acute ST-segment elevation myocardial infarction (AMI). Our aim was to look at the combined results of these trials and to ascertain which reperfusion therapy is most effective.

Methods: We did a search of published work and identified 23 trials, which Cited by:   Background: Post-myocardial infarction ventricular septal defect (VSD) complicates ∼2% of myocardial infarctions.

Thrombolytic therapy may accelerate the time from myocardial infarction to VSD formation. The effects of thrombolytic therapy in patients with a post-myocardial infarction VSD were investigated. Method: Demographic, procedural, and event data were retrospectively analysed in Cited by:   The two major complications of atherosclerosis are acute myocardial infarction (AMI) and acute ischemic stroke.

Both are life-threatening conditions characterised by the abrupt cessation of blood flow to respective organs, resulting in an infarction. Depending on the extent of the infarction, loss of organ function varies considerably. In both conditions, it is possible to limit the extent of Cited by: Guidance on the use of drugs for early thrombolysis in the treatment of acute myocardial infarction Technology appraisal guidance Published: 30 October of AMI for patients requiring thrombolysis for AMI.

Intravenous thrombolytic therapy is an established standard treatment for AMI. Methods Mortality data were ascertained in 20, patients enrolled in the Thrombolysis In Myocardial Infarction (TIMI) 4, 9, and 10B and Intravenous NPA for the Treatment of Infarcting Myocardium Early (InTIME-II) acute MI trials.

Results The frequency of symptomatic recurrent MI during the index hospitalization was % (/20,). Intravenous Thrombolysis in Acute Myocardial Infarction — A Progress Report Arnold S.

Relman, M.D. This article has no abstract; the first words appear by:   5. Physiologic Basis and Results of Thrombolytic Therapy in Acute Myocardial Infarction I.

Introduction II. Physiology of Thrombus Formation and Fibrinolytic Enzyme System III. Early Trials of Long-Duration, Late Intravenous Thrombolytic Therapy in Acute Myocardial Infarction IV.

Intracoronary Streptokinase V. Intravenous Streptokinase Edition: 1. Pell AC, Miller HC, Robertson CE, Fox KA. Effect of "fast track" admission for acute myocardial infarction on delay to thrombolysis. BMJ. Jan 11; ()– [PMC free article] Birkhead JS.

Time delays in provision of thrombolytic treatment in six district by: 6. Anglo-Scandinavian Study of Early Thrombolysis (ASSET) Lancet ii 30 5 AIMS Trial Study Group Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial Lancet i 49 6 Mauri F.

De Blase Am Franzosi Mg Pampallona S. Foresti A. Gasparini M. administration of intracoronary or intravenous thrombolytic agents Although this clinical breakthrough has come in the last 10 years, the pioneering work on this subject was in fact performed in the late s and early s, using open chested anaesthetized dogs to study the effects of reperfusion on ischaemicAuthor: P.

Oldershaw. Introduction. Coronary artery disease (CAD) and its associated side effects are the most common cause of mortality and disability all over the world and its cost burden is the highest among health care costs (1, 2).Currently, each year thousand people are affected with acute myocardial infarction (MI) in the United States, which brings about thousand deaths().Author: Bahareh Feizi, Shahram Taghdisi, Jalil Etemadi, Amir Hossein Feizi, Setareh Asgarzadeh, Sepideh Kama.

Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction.

have shown a substantial beneficial effect of very early thrombolytic therapy. Although these studies were too small to show statistical significance, such Cited by: Early intravenous then oral metoprolol in 45 patients with acute myocardial infarction: randomised placebo-controlled trial.

Previous Article Addition of clopidogrel to aspirin in 45 patients with acute myocardial infarction: randomised placebo-controlled trial. The earliest application ofthrombolytic therapy for acute myocardial infarction involved intravenously administered streptokinase (SK).7 However, early clinical trials thatused intravenous SKorurokinase didnotshow efficacy interms ofmortality reduc-tion Thedisparity between previous findings and thecurrent experience relates totherelatively late.

DISCUSSION. The beneficial effects of thrombolysis in acute myocardial infarction have been recognised for many years. 1 Early treatment with streptokinase in selected cases has been shown to have significant long term benefits on morbidity and mortality.

2 Streptokinase is an enzyme made by haemolytic streptococci, which activates plasminogen by an interaction with its endogenous Cited by:   The incidence of major hemorrhagic events among heparinized patients with acute myocardial infarction who underwent cardiac catheterization in the Thrombolysis in Myocardial Infarction (TIMI) study significantly increased with age, averaging % and % for patients less than 65 years and 70 to 76 years old, respectively/   Although thrombolysis is the commonest form of treatment for acute myocardial infarction, it has important limitations: a rate of recanalisation (restoring normal flow) in 90 minutes of only 55% with streptokinase or 60% with accelerated alteplase; a % risk of early or late reocclusion leading to acute myocardial infarction, worsening ventricular function, or death; a % risk of intracranial haemorrhage Cited by:   “Patency centric” approaches.

With the validation of intravenous thrombolytic treatment versus placebo in the classic GISSI 1 and ISIS 2 trials,1 2 the next step was to determine whether a higher level of early infarct vessel patency would result in improved survival.

This was the focus of the GUSTO 1 trial which showed that a significant increase in patency at 90 minutes after treatment Cited by:   Reperfusion strategies in the early phase of treatment of acute myocardial infarction aim to rapidly normalise and maintain tissue perfusion. Primary angioplasty is probably the best current treatment but it can only be applied to a minority of patients and has its own problems.

Thrombolysis remains the most commonly used treatment. It has well demonstrated benefits, saving lives and Cited by: for the Working Group on Thrombolytic Therapy in Acute Myocardial Infarction of the Netherlands Interuniversity Cardiology Institute* Rotterdam, The Netherlands The effect of thrombolysis in acute myocardial infarction on infarct size, left ventricular function, clinical course and patient survival was studied in a randomized trial.

Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials.

Lancet ; GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med ; The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial.

Eur Heart J ; Oldgren J, Wallentin L, Afzal R, et al. Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment.

Mortality and Prehospital Thrombolysis for Acute Myocardial Infarction: A Meta-Analysis Article in JAMA The Journal of the American Medical Association (20) May with Reads. A convenience sample of 50 patients admitted for treatment or ruling out of acute myocardial infarction were asked about their knowledge of thrombolysis.

Some 44 of 50 knew nothing of thrombolysis and interestingly 30 of these 44 had been previously diagnosed as having ischaemic heart disease. Greater knowledge of the benefit and timeliness of thrombolysis may provide an Cited by: 2. Thrombolysis, also called fibrinolytic therapy, is the breakdown of blood clots formed in blood vessels, using medication.

It is used in ST elevation myocardial infarction, stroke, and in cases of severe venous thromboembolism. The main complication is bleeding, and in some situations thrombolysis may therefore be unsuitable.

Thrombolysis can also play an important part in reperfusion therapy eMedicine: Acute myocardial infarction with ST-segment elevation of more than mV in at least two contiguous leads, excluding V 1 Aspirin and thrombolysis administered within 6 hours of onset of symptoms.

Abstract. Aims We examined the clinical characteristics and outcome of patients with early (and late (>4h) presentation treated by primary angioplasty or thrombolytic therapy for acute myocardial infarction.

Methods and Results We studied patients enrolled in 10 randomized trials of primary angioplasty (n=) vs thrombolytic therapy (n=) in acute Cited by:   Primary percutaneous coronary intervention (PPCI) is the preferred reperfusion strategy in patients with ST-elevation myocardial infarction (STEMI), but its benefit over prehospital fibrinolysis (FL) is not clear.

We performed a systematic review and meta-analysis of randomized controlled trials in which outcomes of patients with STEMI managed with FL early in the prehospital setting versus Cited by: 9.

The proof of efficacy of thrombolysis for acute myocardial infarction (AMI) depends on 9 randomized placebo-controlled trials total. Evidence-based recommendations on using thrombolytic drugs (alteplase [Actilyse], reteplase [Rapilysin], streptokinase [Streptase] and tenecteplase [Metalyse]) for treating acute myocardial infarction in adults.

Is this guidance up to date. We reviewed the evidence in August We found nothing new that affects the recommendations in this guidance. Patients and methods. The trial has been described in detail previously.4 Entry into the trial was based on strong clinical suspicion of acute myocardial infarction by the general practitioner.

Symptoms characteristic of myocardial infarction had to have been present for >/=20 minutes but thrombolytic treatment in Cited by:   Conclusions: Intravenous streptokinase clearly confers a protective effect against early mortality in patients with suspected acute anterior myocardial infarction.

The magnitude of this effect is on the order of a 5% absolute reduction in risk of death by 21 to 35 days. For these patients, 21 need to be treated to save 1 additional by:   If an occlusive thrombus forms, patients may develop an acute ST-segment-elevation myocardial infarction (STEMI), and the primary goal is to consider reperfusion therapy as quickly as possible.

The benefit obtained by effective and early restoration of the global flow (epicardial and microvascular) limits the size of the infarct, reduces the Author: Isaac Pascual Calleja. Plaque rupture and subsequent thrombus formation account for most acute myocardial infarctions (AMIs).

Percutaneous coronary intervention (PCI) is considered the preferred treatment for ST-segment-elevation myocardial infarction (STEMI), for evolving non-STEMI (NSTEMI) and for rescue intervention post-thrombolytics.

1 The main goals of primary and rescue PCI in AMI include Cited by: 3. For instance, the trial titled Intravenous Streptokinase in Acute Myocardial Infarction(ISAM), from Germany (N = ), shows a nonsignificant beneficial trend of. Sunday 8 October, How to give thrombolysis in acute myocardial infarction.

Posted in Emergency, Emergency Dept., Medicine, Michael Tam at by Michael Tam. Original article: Michael Tam:: Printer friendly In the major urban hospitals, there will be little place for thrombolysis in acute STEMI (ST-elevation myocardial infarction).

63897 views Saturday, November 7, 2020